Production (Stage)
Appili Therapeutics Inc.
APLI.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 119.41% | -234.46% | 25.13% | -0.49% | 58.39% |
| Total Depreciation and Amortization | -12.00% | 16.00% | -19.23% | -3.85% | 108.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 353.27% | 1,107.61% | 1,724.35% | 246.88% | -83.45% |
| Change in Net Operating Assets | -143.33% | -346.15% | -6.80% | 109.74% | 51.45% |
| Cash from Operations | 312.75% | -269.80% | 269.63% | 93.59% | 58.70% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 119.23% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -- | -- | -- | 110.20% |
| Total Debt Issued | -- | -- | -100.00% | 166.67% | -100.00% |
| Total Debt Repaid | -77.47% | 1.78% | -34.34% | -84.48% | -13.45% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 37.16% | 26.97% | 11.89% | 2.08% | 91.86% |
| Cash from Financing | -11.81% | 13.95% | -137.82% | 208.74% | -102.39% |
| Foreign Exchange rate Adjustments | 6,971.43% | 3,400.00% | -200.00% | -40.00% | 63.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 292.55% | -324.69% | 386.27% | 110.43% | -149.10% |